Filter posts

New Report: Innovation in Hepatitis C Treatment

Today, the California Healthcare Institute released a report on the public health impact of Hepatitis …

BioCentury TV This Week: 340B Drug Discount Program Needs More Oversight

BIO’s Laurel Todd shared concerns that the 340B program has departed significantly from its original …

Beggar-Thy-Neighbor Medicine: Wall Street Journal Op-Ed

In an editorial about specialty drug prices, the Wall Street Journal writes: “To understand how …

Jim Greenwood Talks 21st Century Cures with Chairman Fred Upton

Recently, BIO CEO and President Jim Greenwood sat down with House Energy and Commerce Chairman …

The Cancer Death-Panel App

In an article for the New York Post, Robert Goldberg, vice president of the Center …

AIR 340B New Report: Contract Pharmacy Growth in 340B

Today, the Alliance for Integrity and Reform of 340B (AIR 340B) released a white paper …

The Value of Prevention

Vaccines are widely recognized as one of the most important advances in medical history. Once-devastating …

Is Regulatory Transformation for Alzheimer’s Therapies Needed?

BIO 2014’s  session titled ” Regulatory Transformation: As Alzheimer’s Disease Science, Research and Advocacy Move …

We Are the Worldview

Now in its 6th consecutive year, Scientific American Worldview: A Global Biotechnology Perspective will have …

NIH, Patients and Industry Ramp Up to AMP-lify Innovation

Speakers at Wednesday’s BIO 2014 Super Session – AMP-lifying Innovation: NIH, Patient Organizations & Leading …